Insider · CIK 0001786966
Badreddin Edris
cooofficerdirector
Files at EWTX (Edgewise Therapeutics, Inc.), SWTX (SpringWorks Therapeutics, Inc.). First filing Dec 5, 2024, latest Mar 5, 2025.
Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
0 / 3
$0 bought, $3.5M sold
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 45Moderate | SpringWorks Therapeutics, Inc. | $1.1M 20,000 shares | -11% | - | |
| 45Moderate | SpringWorks Therapeutics, Inc. | $1.6M 30,000 shares | -14% | - | |
| 31Weak | SpringWorks Therapeutics, Inc. | $839k 20,000 shares | -9% | - |
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jul 1, 2025 | SWTX SpringWorks Therapeutics, Inc. | DDisposition to issuer Common Stock | -169,712 | - | - | 0 | Jul 2, 2025 |
| Jul 1, 2025 | SWTX SpringWorks Therapeutics, Inc. | DDisposition to issuer Performance Share Unitsderivative | -33,778 | - | - | 0 | Jul 2, 2025 |
| Jul 1, 2025 | SWTX SpringWorks Therapeutics, Inc. | DDisposition to issuer Stock Option (Right to Buy)derivative | -3,868 | - | - | 0 | Jul 2, 2025 |
| Jul 1, 2025 | SWTX SpringWorks Therapeutics, Inc. | DDisposition to issuer Stock Option (Right to Buy)derivative | -149,470 | - | - | 0 | Jul 2, 2025 |
| Jul 1, 2025 | SWTX SpringWorks Therapeutics, Inc. | DDisposition to issuer Stock Option (Right to Buy)derivative | -100,000 | - | - | 0 | Jul 2, 2025 |
| Jul 1, 2025 | SWTX SpringWorks Therapeutics, Inc. | DDisposition to issuer Stock Option (Right to Buy)derivative | -240,000 | - | - | 0 | Jul 2, 2025 |
| Jul 1, 2025 | SWTX SpringWorks Therapeutics, Inc. | DDisposition to issuer Stock Option (Right to Buy)derivative | -120,000 | - | - | 0 | Jul 2, 2025 |
| Jul 1, 2025 | SWTX SpringWorks Therapeutics, Inc. | DDisposition to issuer Stock Option (Right to Buy)derivative | -78,960 | - | - | 0 | Jul 2, 2025 |
| Jun 16, 2025 | EWTX Edgewise Therapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +30,000 | $0.00 | $0 | 30,000 | Jun 18, 2025 |
| Mar 3, 2025 | SWTX SpringWorks Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -3,924 | $53.12 | $208k | 185,788 | Mar 5, 2025 |
| Mar 3, 2025 | SWTX SpringWorks Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -12,078 | $54.26 | $655k | 173,710 | Mar 5, 2025 |
| Mar 3, 2025 | SWTX SpringWorks Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -3,598 | $55.12 | $198k | 170,112 | Mar 5, 2025 |
| Mar 3, 2025 | SWTX SpringWorks Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -400 | $56.20 | $22k | 169,712 | Mar 5, 2025 |
| Feb 10, 2025 | SWTX SpringWorks Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -30,000 | $53.13 | $1.6M | 189,712 | Feb 12, 2025 |
| Jan 10, 2025 | SWTX SpringWorks Therapeutics, Inc. | AGrant or award Common Stock | +27,023 | $0.00 | $0 | 219,712 | Jan 14, 2025 |
| Jan 10, 2025 | SWTX SpringWorks Therapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +78,960 | $0.00 | $0 | 78,960 | Jan 14, 2025 |
| Jan 4, 2025 | SWTX SpringWorks Therapeutics, Inc. | FTax withholding Common Stock | -6,934 | $38.19 | $265k | 202,666 | Jan 7, 2025 |
| Jan 5, 2025 | SWTX SpringWorks Therapeutics, Inc. | FTax withholding Common Stock | -5,561 | $38.19 | $212k | 197,105 | Jan 7, 2025 |
| Jan 6, 2025 | SWTX SpringWorks Therapeutics, Inc. | FTax withholding Common Stock | -4,416 | $38.86 | $172k | 192,689 | Jan 7, 2025 |
| Dec 3, 2024 | SWTX SpringWorks Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -11,966 | $41.78 | $500k | 217,634 | Dec 5, 2024 |
| Dec 3, 2024 | SWTX SpringWorks Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -8,034 | $42.24 | $339k | 209,600 | Dec 5, 2024 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.